October 25, 2018 - "The patent outcome enables us to intensify our business development and M&A efforts of broadening our late-stage and commercial product portfolio"
OCTOBER 25, 2018 - In Q3 2018 Orexo delivered yet another strong quarter in terms of net revenue and profitability, when excluding IP litigation costs. The development was primarily driven by a robust contribution from the US commercial operations, where Zubsolv continued its strong performance versus the same quarter in 2017.
OCTOBER 24 2018 - Orexo will host a Capital Markets Day on December 6 in Stockholm, Sweden. Orexo´s mgmt team will then provide a strategy update and give a deeper pipeline insight. Key Note speaker will be the US president´s former advisor on how to combat the #opioidcrisis
We are excited to host a Capital Markets Day on Dec 6 and look forward to welcoming all attendees. During the… https://t.co/REUZNxEfUl